Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | CTSK | P43235 | 4/20 | 0.40 |
| ▸ | CTSS | P25774 | 3/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25075893 | 0.87 | CTSK (0.43) | CTSLCTSKCTSSCA1CA2 | |
| SCHEMBL5142562 | 0.81 | CTSK (0.45) | CA12CA14CTSLCTSKCTSS | |
| SCHEMBL5145931 | 0.81 | CTSK (0.45) | CA12CA14CTSLCTSKCTSS | |
| SCHEMBL31703912 | 0.81 | CTSK (0.45) | CA12CA14CTSLCTSKCTSS | |
| SCHEMBL15510764 | 0.81 | CTSK (0.45) | CA12CA14CTSLCTSKCTSS | |
| SCHEMBL5145936 | 0.81 | CTSK (0.45) | CA12CA14CTSLCTSKCTSS | |
| SCHEMBL15510765 | 0.81 | CTSK (0.45) | CA12CA14CTSLCTSKCTSS | |
| SCHEMBL28252010 | 0.80 | CTSK (0.44) | CA12CA14CTSLCTSKCTSS | |
| SCHEMBL30170429 | 0.79 | KMT2A (0.43) | CA12CA14CTSLCTSKCTSS | |
| SCHEMBL31228503 | 0.79 | CA12 (0.44) | CA12CA14CTSLCTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240277795-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | PARDES BIOSCIENCES INC (US) | 2024-08-22 | — | — | US | disclosed |
| EP-4387980-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-118159548-A | Antiviral compounds | 安力高医药股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| EP-4366831-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| WO-2023023631-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023023631-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023283256-A1 | ANTI-VIRAL COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277795-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CPN1, CTSL | CA12 968/4885CA14 568/4885CTSL 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.